What do we do?

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes ostomy care, urology and continence care, and wound and skin care. We operate globally and employ more than 7,000 people.
Find out more

Brief history

We were founded in 1957 and listed on the Copenhagen Stock Exchange in 1983. We are now the world's leading supplier of intimate healthcare products and services. As a group, we have built our current position by listening to users and understanding their needs.
Find out more

Management

Lars Rasmussen is our CEO and President. Lene Skole is our Executive Vice President and Chief Financial Officer.
Find out more

Financial highlights of 2007/08

• Organic revenue growth was 7%. In addition, contract production lifted revenue growth by 2 percentage points, while exchange rate developments reduced revenue growth by 4 percentage points. Accordingly, revenue measured in Danish kroner was up by 5% to DKK 8,463m
• Organic growth rates by business area: Ostomy Care 6%, Urology & Continence Care 9%, Wound & Skin Care 5%
• Gross profit was up by 3% to DKK 4,998m, equal to a gross margin of 59%. When adjusted for changes in exchange rates, the gross profit was up by 8%, equal to a gross margin of 60%
• EBIT increased by 33% to DKK 994m. Adjusted for changes in exchange rates and non-recurring items, EBIT was up by 3%
• The EBIT margin was 12%, against 9% last year. When adjusted for changes in exchange rates and non-recurring factors, the EBIT margin was 16% and unchanged from last year. Changes in exchange rates reduced the EBIT margin by 1 percentage point
• The profit from continuing operations for the year was DKK 715m against DKK 370m in 2006/07
• The cash inflow from operating activities was up by 24% to DKK 1,324m from DKK 1,064m last year
• Adjusted for business acquisitions and divestments, the 2007/08 free cash flow amounted to DKK 656m, against DKK 376m in 2006/07
• Restructuring costs, especially relating to the production area, impacted the profit for the year by DKK 160m, which amount is recognised under "Special items"
• The Board of Directors recommended that the shareholders who attended the general meeting held on 17 December 2008 approve a dividend of DKK 6.00 per share, compared with the ordinary dividend of DKK 5.00 per share paid last year

Find out more